SOPHIRIS BIO AND NANOBIOTIX
Sophiris Bio (SPHS) has a product called Topsalysin (PRX302) in Phase 2 clinical trial for the treatment of localized prostate. The product is in Phase 3 clinical trial for lower urinary tract symptoms of benign prostatic hyperplasia (BPH).
Topsalysin is a first-in-class, pore-forming protein activated only with the enzymatic action of PSA, which is found in high concentrations around prostate tumor cells and in the transition zone of the prostate. The drug binds to GPI-anchored receptors1 . . .
This content is for paid subscribers.
Today’s Highlights June 27, 2018